Inactive Instrument

Hikal Limited Stock NSE India S.E.

Equities

INE475B01014

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR - Intraday chart for Hikal Limited
Sales 2024 * 18.08B 217M Sales 2025 * 20.78B 249M Capitalization 38.44B 461M
Net income 2024 * 682M 8.19M Net income 2025 * 1.03B 12.38M EV / Sales 2024 * 2.13 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.85 x
P/E ratio 2024 *
57.2 x
P/E ratio 2025 *
37.5 x
Employees -
Yield 2024 *
0.19%
Yield 2025 *
0.19%
Free-Float 30.93%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 50 95-12-31
Founder 76 88-07-07
Director of Finance/CFO - -
Members of the board TitleAgeSince
Founder 76 88-07-07
Chief Executive Officer 50 95-12-31
Director/Board Member 72 92-02-04
More insiders
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
More about the company